Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

New mutations and pathogenesis of myeloproliferative neoplasms.

Blood - 18 Aug 2011

Vainchenker William, Delhommeau François, Constantinescu Stefan N, Bernard Olivier A

Abstract excerpt

Myeloproliferative neoplasms (MPNs) are clonal disorders characterized by excessive production of mature blood cells. In the majority of classic MPN--polycythemia vera, essential thrombocythemia, and primitive myelofibrosis--driver oncogenic mutations affecting Janus kinase 2 (JAK2) or MPL lead to constitutive activation of cytokine-regulated intracellular signaling pathways. LNK, c-CBL, or SOCSs (all negative...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Core Binding Factor Alpha 2 Subunit
Share to Dioxygenases
Share to Enhancer of Zeste Homolog 2 Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Janus Kinase 2

Share to Myeloproliferative Disorders

Share to Polycomb Repressive Complex 2

Share to Proto-Oncogene Proteins

Share to Repressor Proteins

Source

Identifiers

PMID: 21653328
DOI: 10.1182/blood-2011-02-292102

Genes

JAK2
MPL
ASXL1
CBL
TET2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

New mutations and pathogenesis of myeloproliferative neoplasms.PMID 21653328Read ↗

Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1.Semantic proximity Read ↗

Molecular Pathogenesis of Myeloproliferative Neoplasms.Semantic proximity Read ↗

Current outlook on molecular pathogenesis and treatment of myeloproliferative neoplasms.Semantic proximity Read ↗

Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms.Semantic proximity Read ↗

Myeloproliferative neoplasms: Current molecular biology and genetics.Semantic proximity Read ↗

Myeloproliferative neoplasms: updates on molecular pathophysiology, diagnosis and treatment strategies.Semantic proximity Read ↗

Myeloproliferative Neoplasms: Molecular Drivers and Therapeutics.Semantic proximity Read ↗

Molecular pathogenesis of the myeloproliferative neoplasms.Semantic proximity Read ↗

Molecular Pathogenesis of Myeloproliferative Neoplasms: From Molecular Landscape to Therapeutic Implications.Semantic proximity Read ↗

Recent insights regarding the molecular basis of myeloproliferative neoplasms.Semantic proximity Read ↗

Genetic basis and molecular profiling in myeloproliferative neoplasms.Semantic proximity Read ↗

Genetics of the myeloproliferative neoplasms.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.